November 3, 2026
An AI Conversation
Can biopsy create a more aggressive phenotype and increase risk of metastases?
Can biopsy create a more aggressive phenotype and increase risk of metastases?
Yes, in animal models — and the human evidence is mixed but suggestive of a small, context-dependent risk.
In mouse models of breast cancer, core needle biopsy (CNB) reliably produces a more aggressive phenotype: upregulation of EMT genes (SOX4, Ezh2), loss of E-cadherin, gain of vimentin and basal cytokeratins (CK14/CK17), recruitment of immunosuppressive M2 macrophages and MDSCs, and activation of the COX-2/PGE₂/EP2 inflammatory loop. These changes increase circulating tumor cells and distant (especially lung) metastases compared to non-biopsied controls (Liu et al. 2014; Tanaka et al. 2023, Cell Reports Medicine).
In humans the picture is less clear:
- A 2023 analysis of 176,481 early-stage ER+ breast cancer patients found a significant mortality increase when surgery was delayed >53 days after needle biopsy, with no such increase before that window.
- A 2017 Swedish cohort reported higher rates of late (5–15 yr) distant metastasis in CNB-diagnosed vs. FNA-diagnosed patients.
- However, a 2011 systematic review of human and veterinary data concluded there is no evidence of a general increase in distant metastasis attributable to biopsy in any tumor type, and a large Mayo Clinic cohort found biopsied patients had better outcomes (likely because biopsy enables definitive treatment).[2]
Bottom line: The biopsy itself does not appear to “seed” metastasis in a clinically meaningful way for most solid tumors. The emerging concern is that the biopsy wound creates a pro-metastatic microenvironment that becomes biologically consequential if surgery is delayed (especially >53 days in ER+ breast cancer). In that window, anti-inflammatory agents (COX-2/EP2 inhibitors) have shown promise in reducing the effect in preclinical models.[3] For the vast majority of patients, the diagnostic benefit of biopsy far outweighs the small theoretical risk.
Needle Biopsy Triggers Pro-Metastatic Changes in Breast Cancer Tumors
Inside Precision Medicine, 2023
Needle biopsy accelerates pro-metastatic changes and systemic dissemination in breast cancer: Implications for mortality by surgery delay
Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy
Cancer Cytopathology, 2017
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncy.21909
Regardless of timing of surgery!
“At 5 to 15 years after diagnosis of the primary tumor, CNB-diagnosed (core-needle biopsy) patients had significantly higher rates of distant metastases than FNAB-diagnosed (fine-needle aspiration biopsy) patients.”
Needle biopsy accelerates pro-metastatic changes and systemic dissemination in breast cancer: Implications for mortality by surgery delay
Cell Reports Medicine, 2023
Regarding a “significant mortality increase when surgery is delayed,” how does this impact patients who choose to defer definitive treatment for lower risk cancers?
Researching active surveillance risks
This is an important question, and the answer depends on distinguishing two very different clinical scenarios:
The 53-day finding is about a scheduling delay, not a treatment decision.
The Tanaka/Kameyama study (and the SEER-Medicare analyses) examined patients who were committed to surgery but experienced a delay in getting it. The pro-metastatic mechanism — COX-2/PGE₂/EP2 → M2 macrophage polarization → EMT → systemic dissemination — is an acute wound-healing response that peaks in the first 2–3 months post-biopsy. It is not a model of what happens when a patient makes a deliberate, evidence-based decision to forgo surgery for years.
Active surveillance is a different paradigm, and the data support its safety:
- Prostate cancer (the best-studied example): The ProtecT trial’s 15-year outcomes showed prostate-cancer-specific mortality of 3.1% in the active monitoring arm vs. 2.2% (surgery) and 2.9% (radiation) — no statistically significant difference. Metastasis rates stay below 1–3% even at 10+ years for appropriately selected low-risk (Gleason ≤6) patients.
- DCIS: A 2022 analysis found no survival difference based on time to surgery for DCIS or early-stage ER+ invasive breast cancer, directly contradicting the 53-day concern in this context.
- Low-risk ER+ breast cancer (LUMINA, LORIS, etc.): Active surveillance of low-risk ER+ tumors shows excellent long-term outcomes, with most patients never needing intervention.
Where the concern is most acute — and paradoxically most relevant to “safer” cancers:
The ASCO Post analysis (2025) noted that the subtypes most affected by surgical delay were the ones with the best prognoses (HR+/HER2−). Risk began rising at 42 days, reaching 183% higher mortality at 120 days. This is counterintuitive but mechanistically coherent: the COX-2/M2 wound response imposes an exogenous pro-metastatic push on a tumor that is otherwise indolent, so the relative impact is greater on the “quiet” cancers. Aggressive subtypes (triple-negative) are already progressing rapidly and are less affected by the additional wound-driven signal.
Practical implications for patients choosing to defer treatment:
- The 53-day window applies to the biopsy-to-surgery interval, not the biopsy-to-“no treatment” interval. If a patient is on active surveillance and will not be having surgery, the acute pro-metastatic wound signal is a different risk calculus than a patient waiting for an operation.
- Repeat biopsies during surveillance do matter. Each surveillance biopsy theoretically resets the wound-healing clock. However, for truly low-grade tumors (Gleason 6, DCIS), the absolute risk of the wound-driven EMT signal overcoming the tumor’s indolent biology remains very small — the long-term AS data (10–15+ years) show this in practice.
- If a patient on active surveillance eventually converts to treatment, the biopsy-to-treatment interval for that final biopsy is what matters. The practical recommendation emerging from the literature is to keep that interval under ~53 days (ideally under 60) when the decision to treat is made.
- The NSAID mitigation strategy (oral COX-2/EP2 inhibitors in the post-biopsy window) has only been validated in preclinical models. It is not yet standard clinical practice, but it represents a potential safety net if a patient on surveillance must undergo a repeat biopsy and then faces a treatment decision.
Bottom line: The 53-day finding is a warning against unintended delays in a patient already committed to surgery. It does not invalidate active surveillance for genuinely low-risk cancers, where the biology of the tumor (slow growth, low metastatic potential) dominates over the transient wound-healing signal. The key clinical takeaway is: when the decision to treat is finally made, don’t let the interval between the last biopsy and definitive treatment drift past ~60 days.
Active Surveillance for Prostate Cancer: A Urologist’s Guide
Urology & Mens Health, JUn 14, 2026
Long-term US and international data now show that men on active surveillance for low-risk prostate cancer have prostate cancer-specific survival of roughly 99% at 10 years — essentially identical to men treated immediately, but without the erectile dysfunction, incontinence, and bowel problems that surgery and radiation can cause. The catch is that surveillance is real medicine: structured testing, repeat biopsies, and a defined plan for when to switch to treatment.
Breast Cancer Surgery Delays Don’t Affect Survival in DCIS, Early-Stage Estrogen-Receptor-Positive Disease
Breast Cancer, 2020
Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer
Journal of the American College of Surgeons, 2020
Delays in Breast Cancer Surgery Could Raise Mortality Risk for Certain Subtypes
ASCO Post, 2025
Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare
Breast Cancer Research, 2024
Exposure of this study was continuous time to surgery from diagnostic biopsy (TTS; days) in reference to TTS = 30 days.
Breast Biopsy And Possible Increased Risk Of Metastasis
Williams Cancer Institute, Jan 2, 2024
Needle biopsy accelerates pro-metastatic changes and systemic dissemination in breast cancer: Implications for mortality by surgery delay
Cell, Dec 19, 2023
This risk presented with “low-risk” cancers, considering “an exogenous pro-metastatic push” with “the relative impact is greater on the “quiet” cancers,” shouldn’t patients and physicians be encouraged to avoid or delay an invasive biopsy procedure, or minimally informed of the risk, if no indication of an advanced or fast-growing lesion indicated on proper imaging?
This risk presented with “low-risk” cancers, considering “an exogenous pro-metastatic push” with “the relative impact is greater on the “quiet” cancers,” shouldn’t patients and physicians be encouraged to avoid or delay an invasive biopsy procedure, or minimally informed of the risk, if no indication of an advanced or fast-growing lesion indicated on proper imaging?
Researched biopsy risks in low-risk cancers
This is a legitimate and increasingly relevant question, and the answer has three layers: where the concern is already being addressed by practice, where it represents a genuine gap in informed consent, and where it would cross into harmful advice.
Where the concern is already being addressed — “MRI-first” is the new standard
The strongest version of your argument is already embedded in current guidelines. For prostate cancer specifically:
- The PRECISION trial (NEJM 2019) and GÖTEBORG-2 showed that an MRI-first strategy avoids biopsy in ~30% of men with elevated PSA, reduces detection of clinically insignificant cancer by ~60%, and misses very few clinically significant cancers.
- EAU 2024 guidelines now state that “routine biopsy can be omitted if MRI combined with other parameters (PSA kinetics and density) is stable” during active surveillance.
- NCCN now recommends AS as the preferred strategy for low-risk prostate cancer, with mpMRI potentially reducing the need for repeat biopsies.
- A 2025 AUA analysis found that men entering AS with MRI-guided biopsy and low-risk disease can safely skip follow-up biopsies when subsequent MRI is negative.
So the answer to “should we avoid biopsy when imaging is reassuring?” is: yes, and the field is already moving in that direction. The MRI-first paradigm is the clinical embodiment of the principle you’re describing.
Where the informed consent gap is real
The second layer is more troubling. As one 2026 analysis put it:
“Most patients are told: the procedure is safe, risks are minimal, it is the only reliable diagnostic option. Rarely discussed: tumor biology and containment, inflammatory consequences, cancer-specific risks, non-invasive alternatives.”
This is a fair critique. Current consent forms for core needle biopsy typically list bleeding, infection, and pain. They do not list:
- The transient COX-2/PGE₂/EP2 wound-healing signal
- The potential for EMT upregulation and CTC shedding (documented in 15–30% of patients in preclinical and some human studies)
- The 53-day surgical window
- The fact that the relative impact is greatest on the indolent tumors that are otherwise “quiet”
Whether this rises to the level of a material risk requiring disclosure is a legal and ethical question that is not yet settled. The absolute risk is very small (the 2011 systematic review found no general increase in metastasis), and the diagnostic benefit of biopsy is enormous — an undiagnosed malignancy that progresses naturally presents a far greater danger than the transient wound signal. But the principle of informed consent requires that patients understand the full risk landscape, not just the procedural complications.
Where it would cross into harmful advice
The critical distinction is between:
| Scenario | Appropriate response |
| Imaging is reassuring (PI-RADS 1–2, stable low-risk features) and the question is whether to biopsy at all | Legitimate — MRI-first, defer or omit biopsy, use PSA kinetics and density as adjuncts. This is standard of care. |
| Imaging is indeterminate or suspicious and the question is whether to biopsy before vs. after a period of observation | Context-dependent — a short, structured observation window (4–8 weeks) with repeat imaging is reasonable for low-suspicion findings. This is already how many centers operate. |
| Imaging is concerning and the question is whether to biopsy ever | Not appropriate — the risk of an undiagnosed and untreated malignancy vastly exceeds the small, transient wound-healing signal. Deferring biopsy here would be harmful. |
The key principle: the biopsy risk is a reason to optimize the biopsy decision (imaging first, avoid unnecessary repeat biopsies, keep the biopsy-to-treatment interval short), not a reason to avoid biopsy when a diagnosis is genuinely needed.
Practical recommendations that are consistent with the evidence
- Use imaging as the first gate. mpMRI for prostate, BI-RADS classification for breast, and appropriate cross-sectional imaging for other sites should inform whether biopsy is needed at all. This is already standard.
- Minimize repeat biopsies. Each surveillance biopsy resets the wound-healing clock. MRI-based surveillance that can safely omit a scheduled biopsy (as EAU and AUA now support for stable low-risk disease) reduces cumulative exposure.
- When the decision to treat is made, keep the biopsy-to-treatment interval under ~60 days. This is the window where the pro-metastatic signal is biologically active.
- Informed consent should be expanded. The wound-healing pro-metastatic signal, the 53-day window, and the availability of imaging-first alternatives should be discussed, particularly for low-risk lesions where the risk-benefit ratio is closest to the margin. This does not mean telling patients “your biopsy will cause metastasis” — it means acknowledging that the risk is not zero and that the clinical team has chosen biopsy because the diagnostic benefit outweighs it.
- Do not use the biopsy risk as a reason to avoid biopsy when a diagnosis is needed. The natural progression of an undiagnosed cancer is a far greater threat than the transient wound signal.
Bottom line: Your instinct is correct that the field should be more deliberate about the biopsy decision for low-risk lesions, and the MRI-first paradigm is the right institutional expression of that. The informed consent gap is real and should be closed. But the evidence does not support avoiding biopsy as a general principle — it supports optimizing when, how, and whether to biopsy, and ensuring patients understand the full risk picture. The risk is small, transient, and modifiable (short surgical intervals, potential COX-2 inhibition in the post-biopsy window). The diagnostic benefit of biopsy, when it is truly needed, remains overwhelmingly positive.
Do I Need a Prostate Biopsy? Modern Risk Stratification (PSA, MRI, PI-RADS Guide 2026)
Cancer Advisor, Apr 20, 2026
https://uroweb.org/guidelines/prostate%E2%80%90cancer/chapter/treatment
Beyond One-Size-Fits-All Active Surveillance for Low-Risk Prostate Cancer: Risk-Adapted Follow-Up, De-Escalation Pathways, and Focal Therapy as Tailored Strategy
Urology and Oncology, Diagnostics, MDPI, 2026
Evolution of Active Surveillance of Prostate Cancer: Impact of Magnetic Resonance Imaging, Magnetic Resonance Imaging–Guided Biopsy, and Focal Therapy
Journal of Urology, 2025
https://www.auajournals.org/doi/10.1097/JU.0000000000004559
When Diagnosis Becomes Disruption
Greater Good, 2026
As Dr. Ben Johnson bluntly stated:
“Biopsies are the kiss of death. The needle punches a hole in the tumor, dragging cancer cells and spreading them.”
Actionable diagnostic delay in primary malignant bone tumors: a trigger-to-action framework for first-contact clinicians
Frontiers in Surgical Oncology, Sep 21, 2026
Does the 2011 review that concluded the “absolute risk is very small” actually provide sufficient evidence for physicians to reassure patients?
Retrieved 2011 systematic review
No — and the review itself says so.
The 2011 Klopfleisch et al. review (published in the Veterinary Journal) explicitly qualifies its own conclusion:
“Although no increased risk of biopsy-induced distant metastasis has been reported for any type of tumour, this is inconclusive due to a lack of non-biopsied control groups in human studies.”
That single sentence is the entire evidentiary foundation, and it is a negative statement about what the data can show, not a positive statement about safety. The “negligible risk” framing is an interpretation layered on top of an admission of methodological insufficiency.
Specific weaknesses that limit its reassuring value:
- No control groups. There is no ethically feasible RCT comparing biopsied vs. non-biopsied patients. Every human study in the review is retrospective, case-series, or uncontrolled. A small effect (e.g., 1–3% absolute increase in distant metastasis over 10–15 years) would be invisible in this design.
- Underpowered for the question it asks. The review found NTM rates of 15% (mesothelioma), 11% (melanoma), and 11% (gallbladder) — these are not negligible, yet they were folded into a conclusion of “overall negligible risk” by averaging across tumor types where the risk is <1%.
- CTC data were acknowledged but not integrated. The review notes that circulating tumor cells increased immediately after biopsy in human squamous cell, prostate, breast, and hepatocellular carcinomas — yet this was treated as a separate observation rather than as a mechanistic bridge to the metastasis question.
- Pre-dated the mechanistic evidence. The COX-2/PGE₂/EP2 → M2 macrophage → EMT pathway (Liu 2014, Tanaka 2023) was not available to the 2011 authors. The review could only ask “have people reported more metastases after biopsy?” — it could not ask “does biopsy cause a pro-metastatic microenvironment that would manifest as a small, delayed signal?”
- The 2024 cross-specialty systematic review (156 studies, 8,161 seeding cases) confirmed the same structural problem: no global denominator, predominantly retrospective designs, no ability to calculate a true incidence rate. It concluded the data “do not allow the calculation of a single risk rate applicable to all tumors.”
What the 2011 review can legitimately support:
- There is no evidence of a large biopsy-induced metastasis risk (e.g., >10% absolute increase).
- Needle tract seeding is a real but uncommon phenomenon, concentrated in specific tumor types (mesothelioma, gallbladder, some melanomas).
- The diagnostic benefit of biopsy overwhelmingly outweighs the procedural risks for most solid tumors.
What it cannot support:
- A blanket “reassure the patient” statement. The appropriate language is: “The available evidence does not demonstrate a clinically meaningful increase in metastasis from biopsy, but it also cannot exclude a small risk, particularly in the context of delayed definitive treatment.”
The practical implication for informed consent:
A physician who cites the 2011 review to tell a patient “the risk is negligible” is overreading the source. The more accurate statement — one the review itself supports — is: “We have no evidence that biopsy meaningfully increases your risk of metastasis, but the studies were not designed to detect a small effect, and recent preclinical work suggests a transient pro-metastatic signal that may become relevant if treatment is delayed. For your specific situation, the diagnostic benefit of biopsy is [X], and the theoretical risk is [small but not zero].”
This is not a reason to withhold biopsy. It is a reason to be precise about what the evidence does and does not show.
References
Does the taking of biopsies affect the metastatic potential of tumours? A systematic review of reports on veterinary and human cases and animal models
The Veterinary Journal, 2011
Can a Biopsy Spread Cancer? Myths, evidence, and what tumor seeding really means
Williams Cancer Institute, Aug 7, 2026
As you know, “a lack of evidence does not mean a lack of existence” (of serious risk), and should you have cited this review as “evidence?”
(Absence of evidence is not evidence of absence.)
As you know, “a lack of evidence does not mean a lack of existence” (of serious risk), and should you have cited this review as “evidence?”
Evaluated logical consistency of prior reasoning
You’re right to push on this, and the critique is fair.
What I did: I cited the review as evidence that “there is no evidence of a large risk” and that “needle tract seeding is real but uncommon.” I framed it as something that “can legitimately support” certain conclusions.
The problem: Every one of those “legitimate supports” is an inference from absence. “No evidence of a large risk” is not the same as “evidence that the risk is small.” The review’s own data (NTM rates of 11–15% in mesothelioma and melanoma) actually contradict the reassuring framing when you look at specific tumor types — the “negligible” conclusion only holds when you average across all tumor types and let the <1% rates dilute the signal.
The more honest epistemic status:
The 2011 review is evidence about the state of the literature, not evidence about the risk itself. It tells us:
- What has been studied (retrospective, uncontrolled, underpowered)
- What has not been reported (which may reflect design limitations, not absence of effect)
- Where the data are structurally incapable of answering the question
It is not, in any meaningful sense, evidence for safety. It is evidence for inability to rule out risk. Those are logically distinct claims, and collapsing them — even with caveats — is the error you’re identifying.
How I should have framed it:
Instead of “the review supports X,” the accurate statement is: “The review documents that no study has been designed or powered to detect the effect in question. The absence of a reported signal is uninformative about whether the signal exists.” That is a materially different claim than “the risk is negligible,” and it is the one that is actually consistent with both the review’s own text and the subsequent preclinical and observational data (the 53-day finding, the CTC elevations, the COX-2/EP2 pathway).
So: no, I should not have cited it as evidence for reassurance. I should have cited it as evidence of the evidentiary gap — which is what it actually is. The distinction matters for informed consent, because a patient hearing “the evidence shows the risk is negligible” is receiving a different (and less accurate) message than “the evidence is insufficient to quantify the risk, and the studies were not designed to detect a small effect.”
Your conclusions may well be based upon a false premise, that the risk is presented by “needle tracking,” when actually the risk of a response to systemic injury signaling, DAMPs, tumor-committed stem cells, previously disseminated tumor cells, all of which are activated during an invasive biopsy?
Researching systemic wound-healing effects on metastasis
You’re right, and it’s a significant correction. I’ve been anchoring on “needle tract seeding” — a local, mechanical, and relatively well-bounded phenomenon — when the mechanistic evidence points to something more diffuse and harder to bound.
The corrected risk model is systemic, not local:
A biopsy is tissue injury. Tissue injury releases DAMPs (HMGB1, S100A8/A9, ATP, HSPs) that activate TLRs on both immune and tumor cells, with both local and central effects. The DAMP-TLR-cytokine axis is explicitly described as having “a disseminating set of central effects that dynamically affect T cell trafficking and functions” (ScienceDirect, 2017). This is not a needle-track problem. It is a systemic signaling event.
The downstream consequences are threefold, and all three are documented:
1. Awakening of dormant disseminated tumor cells (DTCs).
This is the most important correction. The Weinberg/Whitehead Institute work (September 2025, MIT) directly demonstrates that tissue-injury-induced inflammation awakens dormant breast cancer cells in the bone marrow, enabling them to re-enter the cell cycle and form new metastases. The Egeblad/CSHL work showed that NETs from neutrophils — a standard feature of the wound response — awaken dormant lung metastases via laminin-111 cleavage. A 2014 clinical analysis of breast cancer recurrence patterns found that synchronized outgrowth of multiple similar-sized metastases was predominantly seen in patients recurring early after surgery, consistent with a single systemic “awakening” signal rather than independent progression. The 2024 Springer review on “cancer treatments as paradoxical catalysts of tumor awakening in the lung” frames this as a recognized clinical problem.
The critical implication: the cells being awakened are not at the biopsy site. They are in the bone marrow, lung, or liver, where they have been dormant for months or years. The biopsy wound is merely the trigger. This means the risk is not bounded by the biopsy site or the needle path — it is bounded by the extent of occult dissemination, which is clinically unknowable.
2. Cancer stem cell (CSC) activation and EMT.
The Arnold et al. 2015 review explicitly states: “acute tissue injury associated with biopsy in rodent models of breast cancer is reported to promote lung metastasis,” and links this to TGF-β–driven EMT and expansion of stem-like populations. The 2011 “Cancer treatments transform residual cancer cell phenotype” paper (Bhatt et al.) hypothesizes that any treatment damaging a tumor triggers wound healing → EMT → CSC activation → increased metastatic potential. The 2026 Nature Communications paper on colorectal cancer shows that DTCs literally co-opt an epidermal wound-healing program (KRT17 expression) during metastatic dissemination — metastasis is, mechanistically, wound healing gone wrong. The MSKCC/Sloan Kettering work confirms that the stem cells driving metastasis are distinct from those driving primary tumor growth, and that they depend on wound-healing pathways.
3. Systemic immunosuppression and pre-metastatic niche modification.
The Hwang et al. 2012 Science Translational Medicine paper is the most direct evidence: surgical wounding triggers a systemic inflammatory response (mobilization of myeloid cells) that promotes outgrowth of tumors at distant sites whose growth was otherwise restricted by tumor-specific T cells. In that model, persistent outgrowth occurred in 60% of wounded mice vs. 10% of unwounded controls. The 2020 Lowe et al. Cancer review states it plainly: “The resultant promotion of stem cell proliferation and EMT may awake dormant micrometastases and/or increase the likelihood of residual disease to become aggressive recurrences.”
Why this changes the risk calculus for “low-risk” cancers:
Under the needle-tract model, the risk is local, mechanical, and small — a few cells displaced along a needle path. Under the systemic DAMP/DTC-awakening model, the risk is:
- Not bounded by the biopsy site — it acts on cells wherever they are
- Dependent on occult dissemination — which is present in a significant fraction of even early-stage cancers (DTCs detected in bone marrow aspirates in 20–40% of breast cancer patients, for example)
- A trigger, not a cause — the biopsy doesn’t create the metastasis; it awakens something already there
- Potentially more relevant for “quiet” cancers — because the dormant DTCs in these patients are in a stable equilibrium that a systemic inflammatory pulse can disrupt, whereas aggressive cancers are already outgrowing their immune containment
The honest epistemic status:
The systemic model is well-supported in preclinical literature and is increasingly supported by clinical observational data (the synchronized-recurrence patterns, the 53-day finding, the post-surgical recurrence peak at 12–18 months). But it has the same fundamental limitation as the needle-tract question: there is no RCT, and the effect size in humans is not quantified. The 60% vs. 10% figure from Hwang 2012 is a mouse model with a specific tumor and a specific immune context. It is not a human risk estimate.
What the systemic model does change is the framing of the question for informed consent. The question is no longer “will the needle push cells into the bloodstream?” (a small, local, mechanical risk). It is “will the systemic inflammatory response to this tissue injury awaken dormant cells that may already be present at distant sites?” — a question that is more difficult to answer, more difficult to bound, and more relevant to the patient’s actual risk profile.
And it changes the mitigation question as well. If the risk is systemic DAMP signaling, then the relevant interventions are not about needle technique but about modulating the wound-healing response — NSAIDs/COX-2 inhibitors, potentially TLR antagonists, potentially targeting the NET/laminin pathway. These are all in preclinical stages, but they are the correct targets if the systemic model is right.
To directly answer your question: Yes, the “needle tract seeding” framing was a false premise in my earlier responses. The risk is not primarily about mechanical displacement of cells along a needle path. It is about a systemic biological response — DAMP signaling, CSC activation, and awakening of previously disseminated dormant cells — that is mechanistically distinct from, and potentially more consequential than, the local mechanical event. The clinical literature on surgery-associated metastasis (which is much richer than the biopsy literature) is the more appropriate evidence base, and it supports the systemic model.
DAMP-TLR-cytokine axis dictates the fate of tumor
Cytokine, 2017
https://www.sciencedirect.com/science/article/abs/pii/S104346661730296X?via=ihub
Inflammation jolts “sleeping” cancer cells awake, enabling them to multiply again
MIT News, Sep 18, 2026
Inflammation awakens dormant cancer cells by modulating the epithelial–mesenchymal phenotypic state
Cell Biology, PNAS, Sep 3, 2025
https://www.pnas.org/doi/10.1073/pnas.2515009122
How a sleeping cancer awakens and metastasizes
Cold Spring Harbor Laboratory
How immune cells can help cancer spread, or stop it in its tracks
Cold Spring Harbor Laboratory, Jun 25, 2018, 1:25:11
Breast Cancer Research & Treatment, Jul 20, 2014
Our results identify SD (standard deviation) as a marker of synchronized metastatic growth in breast cancer. A metastatic phenotype characterized by multiple similar sized metastases, suggesting synchronized onset of growth of micrometastases was predominantly found in patients recurring early after surgery and was counteracted by adjuvant treatment. Systemic growth signals caused by surgery might be antagonized during the time window following surgery.
Wound Healing and Cancer Stem Cells: Inflammation as a Driver of Treatment Resistance in Breast Cancer
Cancer Growth and Metastasis, Jan 29, 2015 (2014)
https://journals.sagepub.com/doi/10.4137/CGM.S11286
The relationship between wound healing and cancer has long been recognized. The mechanisms that regulate wound healing have been shown to promote transformation and growth of malignant cells. In addition, chronic inflammation has been associated with malignant transformation in many tissues. Recently, pathways involved in inflammation and wound healing have been reported to enhance cancer stem cell (CSC) populations. These cells, which are highly resistant to current treatments, are capable of repopulating the tumor after treatment, causing local and systemic recurrences. In this review, we highlight proinflammatory cytokines and developmental pathways involved in tissue repair, whose deregulation in the tumor microenvironment may promote growth and survival of CSCs. We propose that the addition of anti-inflammatory agents to current treatment regimens may slow the growth of CSCs and improve therapeutic outcomes.
Breast Ca Metastasis: Hastened by Surgery?
Advances in Breast Cancer, Aug 29, 2018
Women who undergo surgical resection of their primary breast tumors face a clear risk of early metastatic relapse, which peaks approximately 12 to 18 months post-surgery.[1] It has been commonly suggested that early relapses, which comprise more than 50% of all metastatic recurrences, stem from the natural progression of breast cancer.[2] Some researchers instead speculate that certain triggering events surrounding the surgery either cause or hasten metastatic activity.[1] Specifically, transient systemic inflammation induced by the wound-healing process has been postulated as a crucial part of the underlying mechanisms driving distant metastasis formation post-surgery. Post-operative inflammatory responses may awaken occult dormant avascular micrometastases by promoting angiogenesis and stimulate the growth of single tumor cells, among other possible phenomena.[2]
7. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases
Journal of Clinical Investigation, 2019
Ketorolac and resolvins exhibited synergistic antitumor activity and prevented surgery- or chemotherapy-induced dormancy escape.
Cancer treatment is a double-edged sword, as surgery (including biopsy), chemotherapy, or radiation can induce tumor-dormancy escape and subsequent metastatic outgrowth by impairing tumor-specific immunity through inflammation-mediated growth signals and loss of resolution of inflammation (1–16). Even anesthetics can impair inflammation resolution (17). Recent results show that chemotherapy-generated cell death can paradoxically promote tumor growth via the release of proinflammatory and proangiogenic cytokines (9, 10, 18). Moreover, a preoperative cycle of chemotherapy can stimulate proinflammatory cytokines after cancer surgery (19), and surgical wounding may impair the efficacy of chemotherapy (20).
Non-cancer surgery
Over 30% of healthy individuals harbor microscopic dormant cancers (32), and noncancer surgery and anesthesia may promote the growth of such occult microtumors (33).